NVIDIA and Eli Lilly have announced the formation of a dedicated $1 billion AI Lab  a collaborative initiative aimed at reshaping how drugs are discovered, developed, and brought to market. The lab will harness artificial intelligence, high-performance computing, and advanced generative models to accelerate key stages of pharmaceutical research.

Under the partnership, NVIDIA will provide its cutting-edge AI hardware and software stack, including GPU acceleration, large-scale training infrastructure, and optimized neural networks for scientific workflows. Meanwhile, Eli Lilly brings in deep domain expertise in biology, chemistry, pharmacology, and clinical development. Together, the collaborators aim to build tools that shorten discovery timelines, improve prediction accuracy for candidate molecules, and enhance understanding of complex biological systems.

The AI Lab intends to integrate deep learning and generative AI methods into all steps of preclinical research from target identification and compound design to toxicity prediction and early efficacy modeling. By leveraging modern AI approaches, researchers hope to reduce the time and cost associated with traditional trial-and-error methods in drug discovery while opening doors to novel treatments that were previously too complex or costly to pursue.

Senior leaders from both organizations emphasize that this initiative reflects a broader shift in the life-sciences sector toward AI-driven science. They believe that combining AI with biological insight will not only propel innovation but also expand the global pharmaceutical ecosystem’s capacity to tackle unmet medical needs faster than before.